Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
This article was originally published in The Pink Sheet Daily
Executive Summary
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.
You may also be interested in...
Pfizer's Staph Vaccine: Can Narrow Trial Population Support Broader Claim?
US FDA advisory committee will weigh in on clinical development plan for SA4Ag, an S. aureus vaccine for prophylactic use, including whether safety and efficacy data from an ongoing, Phase II trial in spinal surgery patients are generalizable to other elective orthopedic surgical populations.
GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.
GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.